 "Aurobindo Pharma gets 14 observations from the USFDA for Hyderabad plant")
Aurobindo Pharma has received 14 observations from the US health regulator for its Hyderabad-based plant, according to a regulatory filing.
The US Food and Drug Administration (USFDA) inspected company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad from November 4-13, Aurobindo Pharma said.
"At the end of the inspection, we have been issued a Form 483 with 14 observations," it added.
The company believes that none of the observations are related to data integrity issues and, it will respond to the USFDA within the stipulated timeline, Aurobindo Pharma said.
The observations issued by the USFDA notifies the company's management of objectionable conditions at the inspected facility.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app